Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tikun Olam-Cannbit Pharmaceuticals Ltd. is a leading player in the Israeli medical cannabis market, focusing on the cultivation and distribution of cannabis-based products. The company operates in a highly regulated environment, leveraging its unique strains and proprietary formulations to differentiate itself in a competitive landscape.
Tikun Olam-Cannbit generates revenue primarily through the sale of medical cannabis products, which are distributed through pharmacies and healthcare providers. The company benefits from strong pricing power due to its established brand and unique product offerings, including proprietary strains that cater to specific medical conditions.
Regulatory changes impacting cannabis legality and market access
Market demand for medical cannabis products
Partnerships with healthcare providers for product distribution
Research breakthroughs in cannabis applications
Changes in cannabis regulations that could restrict market access
Technological advancements in cannabis cultivation that may increase competition
Emergence of new competitors with innovative products
Price competition from established cannabis producers
High operational losses leading to liquidity concerns
Negative equity position due to accumulated losses
moderate - The demand for medical cannabis can be somewhat resilient during economic downturns, but overall spending on healthcare can be influenced by GDP growth.
Interest rates affect the company's financing costs for expansion and operational investments, potentially impacting profitability and valuation multiples.
minimal - The company has a negative debt/equity ratio, indicating limited reliance on external financing.
growth - Investors are likely attracted to the potential for rapid growth in the medical cannabis sector.
high - The stock has exhibited significant price volatility, reflecting the uncertainties in the cannabis market.